Oakley R S, McCormick W C
Am J Hosp Pharm. 1982 Apr;39(4):594-9.
The literature on reimbursement, especially by third-party payers, for clinical pharmacy services is reviewed. Allocation of total departmental expenses on a per-dose basis, subsidization of clinical pharmacy services through general pharmacy revenues, and inclusion of service charges with drug-product charges have been used successfully to support clinical services. Identification and documentation of benefits resulting from clinical pharmacy services is a vital element in the justification process; a new service has little chance for approval unless it documents cost savings. Published reports of clinical pharmacy services that obtained third-party reimbursement include programs in a cardiac-rehabilitation unit, patient education and monitoring, pharmacokinetics, and laboratory-results interpretation. Published guidelines for obtaining reimbursement for clinical pharmacy services are reviewed. An eight-point guide for obtaining reimbursement is recommended. It embodies: a commitment by the director of pharmacy, via departmental goals and objectives, to clinical services; presentation and acceptance by various key elements in a hospital's structure; accurate analysis of costs and benefits associated with the services; requests for reimbursement from third-party payers; continued analysis of the services' effects; and communication of experience with the services to the general public and the pharmacy profession. It is concluded that reimbursement by third-party payers is a step in the right direction and that clinical service charges should be separated from product charges. Further program development and research are needed.
本文回顾了有关第三方付款人对临床药学服务报销的文献。按每剂量分配部门总费用、通过普通药房收入补贴临床药学服务以及将服务费与药品费用合并,已成功用于支持临床服务。识别和记录临床药学服务产生的效益是论证过程中的关键要素;除非能证明节省成本,否则新服务获批的可能性很小。已获得第三方报销的临床药学服务的公开报告包括心脏康复病房的项目、患者教育与监测、药代动力学以及实验室结果解读。本文回顾了获取临床药学服务报销的已发布指南。推荐了一份获取报销的八点指南。它包括:药房主任通过部门目标对临床服务的承诺;医院结构中各关键要素的呈现与接受;对服务相关成本和效益的准确分析;向第三方付款人申请报销;持续分析服务效果;以及向公众和药学专业人士传播服务经验。得出的结论是,第三方付款人报销是朝着正确方向迈出的一步,临床服务费应与产品费分开。还需要进一步的项目开发和研究。